Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), significantly reduces the incidence of major adverse cardiovascular events (MACE) in the LEADER trial, and has beneficial effects on insulin resistance, liver steatosis and dyslipidemia in T2D patients [16–19]. Here, GLP1R is linked to fatty liver disease.